AG-13958 - 99%, high purity , Vascular endothelial growth factor receptor inhibitor, CAS No.319460-94-1, Vascular endothelial growth factor receptor inhibitor

Item Number

A412773

Grouped product items
SKU	Size	Availability	Price
A412773-1mg	1mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$99.90
A412773-5mg	5mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$329.90
A412773-10mg	10mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$449.90
A412773-25mg	25mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$779.90
A412773-50mg	50mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$1,079.90
A412773-100mg	100mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$1,499.90

VEGFR Inhibitors

View related series

Basic Description

Synonyms	BK72RP7F7D \| N-[2-Fluoro-5-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]amino]phenyl]-2,5-dimethylpyrazole-3-carboxamide \| BCPP000423 \| HY-15492 \| A875759 \| AG13958 \| AG-13958 \| AKOS015904194 \| BCP9000248 \| J-502056 \| CS-0006794 \| (E)-N-(2-fluoro-5-(3-
Specifications & Purity	≥99%
Biochemical and Physiological Mechanisms	AG-13958 (AG-013958), a VEGFR tyrosine kinase inhibitor, is in clinical development with ST administration for treatment of choroidal neovascularization associated with age–related macular degeneration (AMD).
Storage Temp	Protected from light,Store at -20°C
Shipped In	Ice chest + Ice pads
Action Type	INHIBITOR
Mechanism of action	Vascular endothelial growth factor receptor inhibitor
Product Description	Information AG-13958 AG-13958 (AG-013958), a VEGFR tyrosine kinase inhibitor, is in clinical development with ST administration for treatment of choroidal neovascularization associated with age–related macular degeneration (AMD). Targets VEGFR

Associated Targets

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

Names and Identifiers

IUPAC Name	N-[2-fluoro-5-[[3-[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-yl]amino]phenyl]-2,5-dimethylpyrazole-3-carboxamide
INCHI	InChI=1S/C26H22FN7O/c1-16-13-25(34(2)33-16)26(35)30-24-15-19(7-10-21(24)27)29-18-6-9-20-22(31-32-23(20)14-18)11-8-17-5-3-4-12-28-17/h3-15,29H,1-2H3,(H,30,35)(H,31,32)/b11-8+
InChi Key	JXSVVZKPEDIRTN-DHZHZOJOSA-N
Canonical SMILES	CC1=NN(C(=C1)C(=O)NC2=C(C=CC(=C2)NC3=CC4=C(C=C3)C(=NN4)C=CC5=CC=CC=N5)F)C
Isomeric SMILES	CC1=NN(C(=C1)C(=O)NC2=C(C=CC(=C2)NC3=CC4=C(C=C3)C(=NN4)/C=C/C5=CC=CC=N5)F)C
PubChem CID	9934283
Molecular Weight	467.51

Solubility

Solubility (25°C) In vitro DMSO: 94 mg/mL (201.06 mM); Water: Insoluble; Ethanol: Insoluble;

Sensitivity

Moisture sensitive；Light sensitive

Solution Calculators

Determine the necessary mass, volume, or concentration for preparing a solution.

Determine the dilution needed to prepare a stock solution.

Basic Description